Andrew P. Thomas

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

Stephen R. Wedge, Donald Ogilvie, Michael Dukes et al. · PubMed · 2002 · 802 citations

Oral Administration, Pharmacotherapy, Tumor Biology +18

AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family

Paul R. Gavine, Lorraine Mooney, Elaine Kilgour et al. · Cancer Research · 2012 · 491 citations

Fgfr Selectivity, Kinase Inhibitors, Pharmacotherapy +16

Novel 4-Anilinoquinazolines with C-7 Basic Side Chains:  Design and Structure Activity Relationship of a Series of Potent, Orally Active, VEGF Receptor Tyrosine Kinase Inhibitors

Laurent Hennequin, Elaine S. E. Stokes, Andrew P. Thomas et al. · Journal of Medicinal Chemistry · 2002 · 308 citations · Full text

Combinatorial Chemistry, Tyrosine Kinase, Orally Active +16

Mitochondria Suppress Local Feedback Activation of Inositol 1,4,5-Trisphosphate Receptors by Ca2+

György Hajnóczky, Richard Hager, Andrew P. Thomas · Journal of Biological Chemistry · 1999 · 263 citations · Full text

Ca2+ Uptake, Cellular Physiology, Inositol 1,4,5-Trisphosphate Receptors +16

Design and Structure−Activity Relationship of a New Class of Potent VEGF Receptor Tyrosine Kinase Inhibitors

Laurent Hennequin, Andrew P. Thomas, Craig Johnstone et al. · Journal of Medicinal Chemistry · 1999 · 235 citations · Full text

Medicinal Chemistry, Drug Target, Biochemistry +15